Myomo Inc. (NYSE:MYO) is a pioneering medical robotics company at the forefront of neurorehabilitation technology, committed to restoring independence and mobility to individuals suffering from upper-limb paralysis and neuromuscular disorders. Headquartered in Burlington, Massachusetts, the company has earned national and international recognition for its innovative approach to assistive robotics through its flagship product line, the MyoPro®.
Founded with origins out of the Massachusetts Institute of Technology (MIT) and Harvard Medical School, Myomo — short for “my own motion” — has developed a breakthrough solution that blends biomedical engineering, neuroscience, and robotics. The company’s proprietary technology allows individuals who have suffered from stroke, spinal cord injury, brachial plexus injury, or other neurological impairments to regain functional use of their arms and hands.
The MyoPro orthosis is the first and only FDA-cleared, non-invasive, myoelectric-powered device in the United States that senses weak electrical muscle signals (EMG) through sensors placed on the skin and then activates motors to move the arm and hand. This allows users to perform essential daily tasks such as eating, lifting objects, writing, and more — tasks many had previously lost the ability to perform due to their conditions. The impact goes beyond physical rehabilitation; many patients are able to return to work, reduce caregiver dependency, and improve their overall quality of life.
Myomo’s business model is built around a combination of direct-to-patient outreach, clinical partnerships, and a growing network of Certified Prosthetists Orthotists (CPOs) across the United States. The company has made significant progress in securing reimbursement from major payers, including Medicare and private insurers, making its life-changing technology more accessible to the broader population. With a growing number of MyoPro Centers of Excellence and an expanding pipeline of qualified candidates, Myomo continues to scale its operations while remaining laser-focused on patient outcomes.
As the aging population rises and neurological conditions become more prevalent, Myomo is positioned at the intersection of high-impact healthcare innovation and exponential market opportunity. It is not just developing devices—it is delivering motion, restoring dignity, and empowering patients to reclaim control over their lives. Myomo represents a rare combination of mission-driven technology and scalable business strategy, making it one of the most compelling growth stories in the wearable medical robotics industry today.
Q1 2025 Results Mark a Significant Turning Point for Myomo’s Growth Trajectory
Myomo’s financial performance for the first quarter of 2025 serves as a compelling validation of its market position and operational execution. Revenue for the quarter reached $9.8 million, reflecting a staggering 162% year-over-year increase from $3.75 million in Q1 2024. This surge was driven by robust growth in revenue units — up 100% year-over-year to 182 — with 45% of these units stemming from orders and authorizations received during the same quarter, showcasing unprecedented velocity in Myomo’s sales pipeline.
Average selling price (ASP) of the MyoPro reached approximately $54,000, a 31% increase compared to the prior year, fueled in part by Medicare Part B patients, who contributed 59% of total revenue. This performance underscores the growing acceptance of MyoPro devices by CMS and the expanding reach of Myomo’s direct billing capabilities.
Gross margin expanded meaningfully to 67.2%, up from 61.2% a year ago, highlighting better inventory management and the benefit of higher ASPs. The company recorded a gross profit of $6.6 million, a 187% increase from Q1 2024.
CHECK THIS OUT: Lakeside Holding Limited (LSH): Key Insights and Strategic Developments and Lakeside Holding (LSH) Deepens Roots in Pharmaceutical Logistics with $1.5M Sinopharm Agreement.
Robust Patient Pipeline and Operational Efficiency Signal Long-Term Upside
Equally impressive was the rapid expansion of Myomo’s patient pipeline. A record-breaking 700 new candidates were added in Q1 2025, a 42% increase from the same period last year, bringing the total pipeline to 1,482 medically qualified individuals — up 33% year-over-year. This surge came despite a challenging environment early in the quarter, as social media algorithm changes temporarily disrupted digital lead generation, inflating the cost per pipeline addition to $2,300, up 31% from the previous year. However, by March and April, lead flow and candidate additions had rebounded strongly, signaling that the disruption was temporary.
On the operations front, the company received 213 MyoPro authorizations and orders in Q1, marking an 18% increase year-over-year. Although the ending backlog stood at 249 units — a 9% decrease compared to the prior year — this is largely a function of faster conversion of orders into recognized revenue, which is a net positive indicator of the company’s operational efficiency.
Strategic Scaling Through Certified MyoPro Centers of Excellence
A core component of Myomo’s go-to-market strategy involves the training and certification of clinical partners. As of the end of Q1 2025, over 300 Certified Prosthetists Orthotists (CPOs) had completed initial MyoPro training, helping the company deepen its distribution network and enhance local service capabilities across the U.S. MyoPro certification classes are ongoing, enabling Myomo to scale its impact and reduce patient onboarding time. This initiative will likely yield long-term benefits by establishing a national footprint of certified professionals capable of delivering personalized, high-quality care.
Operating Loss Narrows as Myomo Marches Toward Profitability
While Myomo remains in a scaling phase, signs of improved cost discipline and operational leverage are emerging. The company reported an operating loss of $3.5 million in Q1 2025, a narrowing from the $3.9 million loss posted in the same quarter of 2024. Net loss also decreased to $3.5 million or $0.08 per share, compared to $3.8 million or $0.10 per share last year. Adjusted EBITDA improved to $(2.8) million from $(3.5) million, providing further evidence that the company is making meaningful progress toward breakeven.
Cash, cash equivalents, and short-term investments stood at $21.5 million as of March 31, 2025, with cash usage for operations amounting to $2.7 million — down from $3.2 million in the prior year. Myomo’s relatively modest cash burn combined with its expanding revenue base and high-margin profile suggest a strong runway ahead for scaling without immediate dilution or capital pressure.
Business Outlook for 2025 Reinforces a Bullish Setup
Looking ahead, Myomo expects Q2 revenue to range between $9.0 million and $9.5 million, reflecting lingering effects of the lead generation challenges from early Q1. However, the company reiterated full-year guidance of $50 million to $53 million, representing a year-over-year increase of 54% to 63%. Management anticipates revenue acceleration in the second half of the year as marketing efficiency improves and the patient pipeline continues to grow.
CEO Paul R. Gudonis emphasized that the company remains on track to achieve positive cash flow from operations on a quarterly basis by Q4 2025. This inflection point would mark a major milestone in Myomo’s evolution from a development-stage medtech innovator to a scalable, revenue-generating leader in the medical robotics industry.
Why MYO Stock Presents a High-Conviction Growth Opportunity
Myomo’s strategic position is reinforced by several durable tailwinds. The company operates at the convergence of aging demographics, expanded Medicare reimbursement, rising demand for functional independence, and the growing prevalence of post-stroke and neurological disorders. As a first-mover in a highly specialized niche with proprietary technology, Myomo has a defensible competitive moat.
Analysts covering the stock maintain a bullish outlook, with price targets ranging from $9.13 to $11.50, implying significant upside from current levels. With gross margins trending upward, a scalable commercial model, and a differentiated value proposition backed by real-world impact, MYO stock represents a compelling long-term investment.
Conclusion: Myomo is More Than a Medtech Stock — It’s a Movement Toward Independence
Myomo’s Q1 2025 results reinforce the narrative of a company hitting its stride across multiple growth vectors — revenue, patient engagement, clinical adoption, and operating leverage. As the company continues to expand its clinical network, deepen its pipeline, and execute on its roadmap to profitability, investors should view MYO not only as a high-growth medical technology play but as a transformative force in the future of assistive healthcare.
With its unique product, improving financials, and powerful mission, Myomo is well-positioned to deliver shareholder value while restoring freedom and dignity to thousands of lives.
READ ALSO: Lakeside Holding (LSH) Acquires Hupan Pharmaceutical to Enter China’s Medical Logistics Market and Lifeway Foods (LWAY): Probiotic Pioneer Targets $195M Revenue in 2024.
